Research programme: polyribitol phosphate antibody therapeutics - Amorfix Life Sciences

Drug Profile

Research programme: polyribitol phosphate antibody therapeutics - Amorfix Life Sciences

Alternative Names: AMF-1c-120; Anti-PrP antibodies - Amorfix; DSE3 ab120; DSE3 ab120/urease

Latest Information Update: 18 Dec 2014

Price : $50

At a glance

  • Originator Amorfix Life Sciences
  • Developer Helix BioPharma; ProMIS Neurosciences
  • Class Drug conjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Polyribitol phosphate inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Ovarian cancer

Most Recent Events

  • 08 Aug 2014 Suspended - Preclinical for Ovarian cancer in Canada (Parenteral)
  • 09 Apr 2013 Pharmacodynamics data from a preclinical study in Ovarian cancer released by Amorfix
  • 18 Jul 2012 Research programme is available for licensing as of 30 Apr 2012. http://www.amorfix.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top